Table of Contents
Chemotherapy Research and Practice
Volume 2013 (2013), Article ID 726925, 7 pages
http://dx.doi.org/10.1155/2013/726925
Clinical Study

High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases

1Department of Dermatology, Anheuser-Busch Institute, Saint Louis University, 1402 S. Grand Boulevard., 4th Floor, St. Louis, MO 63104, USA
2Division of Hematology and Oncology, Saint Louis University, 3655 Vista Avenue, 3rd Floor, St. Louis, MO 63110, USA
3Center for Outcomes Research, Saint Louis University, 3545 Lafayette Avenue, 4th Floor, St. Louis, MO 63104, USA
4Division of General Surgery, Saint Louis University, 3655 Vista Avenue, St. Louis, MO 63110, USA

Received 26 February 2013; Revised 20 April 2013; Accepted 22 April 2013

Academic Editor: Vassilios A. Georgoulias

Copyright © 2013 Melinda B. Chu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Proleukin (aldesleukin) [package insert],” Prometheus Laboratories, San Diego, Calif, USA, August 2011.
  2. G. K. Antony and A. Z. Dudek, “Interleukin 2 in cancer therapy,” Current Medicinal Chemistry, vol. 17, no. 29, pp. 3297–3302, 2010. View at Google Scholar · View at Scopus
  3. A. M. M. Eggermont and D. Schadendorf, “Melanoma and Immunotherapy,” Hematology/Oncology Clinics of North America, vol. 23, no. 3, pp. 547–564, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. P. W. Sperduto, S. T. Chao, P. K. Sneed et al., “Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients,” International Journal of Radiation Oncology Biology Physics, vol. 77, no. 3, pp. 655–661, 2010. View at Publisher · View at Google Scholar
  5. J. S. Barnholtz-Sloan, A. E. Sloan, F. G. Davis, F. D. Vigneau, P. Lai, and R. E. Sawaya, “Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit cancer surveillance system,” Journal of Clinical Oncology, vol. 22, no. 14, pp. 2865–2872, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. M. H. Amer, M. Al-Sarraf, L. H. Baker, and V. K. Vaitkevicius, “Malignant melanoma and central nervous system metastases. Incidence, diagnosis, treatment and survival,” Cancer, vol. 42, no. 2, pp. 660–668, 1978. View at Google Scholar · View at Scopus
  7. J. M. Skibber, S. J. Soong, L. Austin, C. M. Balch, and R. E. Sawaya, “Cranial irradiation after surgical excision of brain metastases in melanoma patients,” Annals of Surgical Oncology, vol. 3, no. 2, pp. 118–123, 1996. View at Google Scholar · View at Scopus
  8. J. K. Patel, M. S. Didolkar, J. W. Pickren, and R. H. Moore, “Metastatic pattern of malignant melanoma. A study of 216 autopsy cases,” The American Journal of Surgery, vol. 135, no. 6, pp. 807–810, 1978. View at Google Scholar · View at Scopus
  9. E. Fonkem, E. J. Uhlmann, S. R. Floyd et al., “Melanoma brain metastases: overview of current management and emerging targeted therapies,” Expert Review of Neurotherapeutics, vol. 12, no. 10, pp. 1207–1215, 2012. View at Google Scholar
  10. G. T. Gibney, P. A. Forsyth, and V. K. Sondak, “Melanoma in the brain: biology and therapeutic options,” Melanoma Research, vol. 22, no. 3, pp. 177–183, 2012. View at Google Scholar
  11. L. M. Guirguis, J. C. Yang, D. E. White et al., “Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases,” Journal of Immunotherapy, vol. 25, no. 1, pp. 82–87, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Powell and A. Z. Dudek, “Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases,” Anticancer Research, vol. 29, no. 10, pp. 4189–4193, 2009. View at Google Scholar · View at Scopus
  13. J. H. Howard, J. F. Thompson, N. Mozzillo et al., “Metastasectomy for distant metastatic melanoma: analysis of data from the first multicenter selective lymphadenectomy trial (MSLT-I),” Annals of Surgical Oncology, vol. 19, no. 8, pp. 2547–2555, 2012. View at Publisher · View at Google Scholar
  14. D. N. Liew, H. Kano, D. Kondziolka et al., “Outcome predictors of gamma knife surgery for melanoma brain metastases: clinical article,” Journal of Neurosurgery, vol. 114, no. 3, pp. 769–779, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. K. N. Heller, A. C. Pavlick, F. S. Hodi et al., “Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases,” Journal of Clinical Oncology, vol. 29, abstract no. 8581, 2011. View at Google Scholar
  16. R. Dummer, J. Rinderknecht, S. M. Goldfinger et al., “An open-label study of vemurafenib in previous treated metastatic melanoma patients with brain metastases,” Journal of Clinical Oncology, vol. 29, abstract no. 8548, 2011. View at Google Scholar
  17. K. Margolin, M. S. Ernstoff, O. Hamid et al., “Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial,” The Lancet Oncology, vol. 13, no. 5, pp. 459–465, 2012. View at Publisher · View at Google Scholar
  18. F. S. Hodi, M. Sznol, D. F. McDermott et al., “Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma,” Journal of Clinical Oncology, vol. 30, abstract no. 8507, 2012. View at Google Scholar